Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Let-7e suppresses DNA damage repair and sensitizes ovarian cancer to cisplatin through targeting PARP1.
|
31722968 |
2020 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Women with epithelial ovarian cancer (OC) have a higher chance to benefit from PARP inhibitor (PARPi) therapy if their tumor has a somatic or hereditary BRCA1/2 pathogenic variant.
|
31076742 |
2020 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibitors of nuclear poly(ADP-ribose) polymerase (PARP) enzymes (e.g., PARP-1) have improved clinical outcomes in ovarian cancer, especially in patients with BRCA1/2 gene mutations or additional homologous recombination (HR) DNA repair pathway deficiencies.
|
31594824 |
2020 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mechanisms of PARP inhibitor resistance in ovarian cancer.
|
31815769 |
2020 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers.
|
31669203 |
2020 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP inhibitors have transformed the management of advanced high-grade serous ovarian cancer.
|
31630846 |
2020 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP1 plays a crucial role in multiple biological processes and PARP1 activation contributes to the development of various inflammatory and malignant disorders, including lung inflammatory disorders, cardiovascular disease, ovarian cancer, breast cancer, and diabetes.
|
31500199 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy.
|
31653094 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, combined inhibition of PARP and Wnt/β-catenin showed synergistic suppression of PARPi-resistant cells <i>in vitro</i> and <i>in vivo</i> in a xenograft EOC mouse model.
|
30967398 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we discuss HR deficiency hallmarks as predictive biomarkers for platinum salt and PARP inhibitor sensitivity for selecting patients affected by TNBC or epithelial ovarian cancer who could benefit from these therapeutic options.
|
30661659 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
GnRH-R-Targeted Lytic Peptide Sensitizes <i>BRCA</i> Wild-type Ovarian Cancer to PARP Inhibition.
|
30926640 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP inhibitors in ovarian cancer.
|
30543930 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP inhibitors (PARPi) represent a major advance in the treatment of ovarian cancer associated with defects in homologous recombination DNA repair (HRR), primarily due to mutations in BRCA genes.
|
30342021 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PARP inhibitors (PARPis) have remarkable antitumor activity in BRCA mutant ovarian carcinoma.
|
30666631 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Success for First-Line PARP Inhibition in Ovarian Cancer.
|
31591108 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
|
30551885 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the past few years, the advent of PARP inhibitors has been a revolution in the management of ovarian cancer.
|
31335830 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, 3 new PARP inhibitors (olaparib, rucaparib, niraparib) have been approved for use in ovarian cancer, with different indications as maintenance therapy or treatment of recurrence.
|
31117037 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Maintenance therapy with PARP inhibitors has heralded a new era in the management of recurrent epithelial ovarian cancer.
|
31037967 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
|
29567272 |
2018 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.
|
30540933 |
2018 |
Carcinoma, Ovarian Epithelial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The single agent activity of PARP inhibitors (PARPi) in germline BRCA mutated (gBRCAm) breast and ovarian cancer suggests untapped potential for this new class of drug in breast cancer.
|
29644491 |
2018 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Olaparib (Lynparza™) is a PARP inhibitor approved for advanced BRCA-mutated (BRCAm) ovarian cancer.
|
30353044 |
2018 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study provides mechanistic rationales for combining CNDAC with PARP inhibitors, platinum compounds and taxanes in ovarian cancer lacking BRCA1/2 function.
|
29189915 |
2018 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
|
29464354 |
2018 |